|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1996-5-24
|
|
pubmed:abstractText |
Didemnin B (NSC #335319) was administered i.v. to 26 evaluable patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix at 6.3 mg/m(2) every 28 days until progression of disease. No patient had had prior cytotoxic therapy alone. Some patients (4) were exposed to radiation sensitizers. There was one complete responder (4.5%). Six patients had stable disease (27.3%) and 15 (68.2%) had increasing disease. The toxicities were significant, with 11 patients (42.3%) experiencing grade 3 or 4 adverse effects. Didemnin B, when used with this dose and schedule, has minimal activity in squamous cell carcinoma of the cervix.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0277-3732
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
184-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8610646-Adult,
pubmed-meshheading:8610646-Aged,
pubmed-meshheading:8610646-Aged, 80 and over,
pubmed-meshheading:8610646-Antiemetics,
pubmed-meshheading:8610646-Antineoplastic Agents,
pubmed-meshheading:8610646-Blood Coagulation,
pubmed-meshheading:8610646-Carcinoma, Squamous Cell,
pubmed-meshheading:8610646-Depsipeptides,
pubmed-meshheading:8610646-Disease Progression,
pubmed-meshheading:8610646-Drug Administration Schedule,
pubmed-meshheading:8610646-Female,
pubmed-meshheading:8610646-Humans,
pubmed-meshheading:8610646-Injections, Intravenous,
pubmed-meshheading:8610646-Middle Aged,
pubmed-meshheading:8610646-Nausea,
pubmed-meshheading:8610646-Neoplasm Recurrence, Local,
pubmed-meshheading:8610646-Peptides, Cyclic,
pubmed-meshheading:8610646-Radiation-Sensitizing Agents,
pubmed-meshheading:8610646-Remission Induction,
pubmed-meshheading:8610646-Uterine Cervical Neoplasms,
pubmed-meshheading:8610646-Vomiting
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Albany Medical Center Hospital, Buffalo, New York, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|
